Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gavin Churchyard

Showing results (31-40 of 135) with videos related to

Pageof 14
Sort By:
Plos Medicine|January 4, 2007
Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic diseaseElizabeth L Corbett, Tsitsi Bandason, Yin Bun Cheung, et al.
Plos One|November 18, 2014
Uptake of genital mucosal sampling in HVTN 097, a phase 1b HIV vaccine trial in South AfricaErica Maxine Lazarus, Kennedy Otwombe, Tania Adonis, et al.
Plos One|May 14, 2021
Strengthening health systems to improve the value of tuberculosis diagnostics in South Africa: A cost and cost-effectiveness analysisNicola Foster, Lucy Cunnama, Kerrigan McCarthy, et al.
Plos One|May 9, 2025
Resistance to tuberculin skin test/interferon-gamma release assay conversion among highly TB exposed, HIV infected goldminers in South AfricaThobani Ntshiqa, Kavindhran Velen, Sibuse Ginindza, et al.
Plos One|August 5, 2014
Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responsesKathryn L Hopkins, Fatima Laher, Kennedy Otwombe, et al.
The Lancet. Global Health|July 20, 2023
Impact and cost-effectiveness of short-course tuberculosis preventive treatment for household contacts and people with HIV in 29 high-incidence countries: a modelling analysisTheresa Ryckman, Jeff Weiser, Makaita Gombe, et al.
Health Economics|January 15, 2016
Using Top-down and Bottom-up Costing Approaches in LMICs: The Case for Using Both to Assess the Incremental Costs of New Technologies at ScaleLucy Cunnama, Edina Sinanovic, Lebogang Ramma, et al.
The Journal of Infectious Diseases|August 15, 2013
Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switchVictoria Johnston, Karen Cohen, Lubbe Wiesner, et al.
Plos One|January 26, 2019
Application of provincial data in mathematical modelling to inform sub-national tuberculosis program decision-making in South AfricaPiotr Hippner, Tom Sumner, Rein Mgj Houben, et al.
BMC Medicine|May 17, 2022
Prioritising attributes for tuberculosis preventive treatment regimens: a modelling analysisJuan F Vesga, Christian Lienhardt, Placide Nsengiyumva, et al.
Pageof 14

Showing results (31-40 of 135) with videos related to

Sort By:
Pageof 14
Plos Medicine|January 4, 2007
Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic diseaseElizabeth L Corbett, Tsitsi Bandason, Yin Bun Cheung, et al.
Plos One|November 18, 2014
Uptake of genital mucosal sampling in HVTN 097, a phase 1b HIV vaccine trial in South AfricaErica Maxine Lazarus, Kennedy Otwombe, Tania Adonis, et al.
Plos One|May 14, 2021
Strengthening health systems to improve the value of tuberculosis diagnostics in South Africa: A cost and cost-effectiveness analysisNicola Foster, Lucy Cunnama, Kerrigan McCarthy, et al.
Plos One|May 9, 2025
Resistance to tuberculin skin test/interferon-gamma release assay conversion among highly TB exposed, HIV infected goldminers in South AfricaThobani Ntshiqa, Kavindhran Velen, Sibuse Ginindza, et al.
Plos One|August 5, 2014
Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responsesKathryn L Hopkins, Fatima Laher, Kennedy Otwombe, et al.
The Lancet. Global Health|July 20, 2023
Impact and cost-effectiveness of short-course tuberculosis preventive treatment for household contacts and people with HIV in 29 high-incidence countries: a modelling analysisTheresa Ryckman, Jeff Weiser, Makaita Gombe, et al.
Health Economics|January 15, 2016
Using Top-down and Bottom-up Costing Approaches in LMICs: The Case for Using Both to Assess the Incremental Costs of New Technologies at ScaleLucy Cunnama, Edina Sinanovic, Lebogang Ramma, et al.
The Journal of Infectious Diseases|August 15, 2013
Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switchVictoria Johnston, Karen Cohen, Lubbe Wiesner, et al.
Plos One|January 26, 2019
Application of provincial data in mathematical modelling to inform sub-national tuberculosis program decision-making in South AfricaPiotr Hippner, Tom Sumner, Rein Mgj Houben, et al.
BMC Medicine|May 17, 2022
Prioritising attributes for tuberculosis preventive treatment regimens: a modelling analysisJuan F Vesga, Christian Lienhardt, Placide Nsengiyumva, et al.
Pageof 14